Utility of interval kidney biopsy in ANCA-associated vasculitis. (10th September 2021)

• Record Type: Journal Article
• Authors: Chapman, Gavin B; Farrah, Tariq E; Chapman, Fiona A; Pugh, Dan; Bellamy, Christopher O C; Lahiri, Rashmi; Miller-Hodges, Eve; Kluth, David C; Hunter, Robert W; Dhaun, Neeraj
• Is Part Of: Rheumatology. Volume 61:Number 5(2022)
• Page Start: 1966
• Page End: 1974
• Publication Date: 2021-09-10
• Subjects: ANCA vasculitis -- interval kidney biopsy -- hematuria; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keab695
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: ANCA-associated vasculitis (AAV) is a rare autoimmune disorder that commonly involves the kidney. Early identification of kidney involvement, assessing treatment-response and predicting outcome are important clinical challenges. Here, we assessed the potential utility of interval kidney biopsy in AAV. Methods: In a tertiary referral centre with a dedicated vasculitis service, we identified patients with AAV who had undergone interval kidney biopsy, defined as a repeat kidney biopsy (following an initial biopsy showing active AAV) undertaken to determine the histological response in the kidney following induction immunosuppression. We analysed biochemical, histological and outcome data, including times to kidney failure and death for all patients. Results: We identified 57 patients with AAV who underwent at least one interval kidney biopsy (59 interval biopsies in total; median time to interval biopsy ∼130 days). Of the 59 interval biopsies performed, 24 (41%) patients had clinically suspected active disease at time of biopsy which was confirmed histologically in only 42% of cases; 35 (59%) patients were in clinical disease-remission, and this was correct in 97% of cases. The clinician's impression was incorrect in one in four patients. Hematuria at interval biopsy did not correlate with histological activity. Interval biopsy showed fewer acute lesions and more chronic damage compared with initial biopsy and led to immunosuppressive treatment-change in 75% (44/59) of patients. Clinical risk prediction tools tended to operate better using interval biopsy data. Conclusion: Interval kidney biopsy is useful for determining treatment-response and subsequent disease management in AAV. It may provide better prognostic information than initial kidney biopsy and should be considered for inclusion into future clinical trials and treatment protocols for patients with AAV.